Cargando…
STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity
Combining different immunotherapy approaches is currently building the future of immunotherapy, with the view to maximize anti-tumoral efficacy for larger patient population. The KISIMA™ platform allows the development of protein-based cancer vaccines able to induce tumor-specific T cell response re...
Autores principales: | Rossi, Matteo, Carboni, Susanna, Di Berardino-Besson, Wilma, Riva, Erika, Santiago-Raber, Marie-Laure, Belnoue, Elodie, Derouazi, Madiha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283310/ https://www.ncbi.nlm.nih.gov/pubmed/34276686 http://dx.doi.org/10.3389/fimmu.2021.695056 |
Ejemplares similares
-
Heterologous Prime-Boost Vaccination with a Peptide-Based Vaccine and Viral Vector Reshapes Dendritic Cell, CD4+ and CD8+ T Cell Phenotypes to Improve the Antitumor Therapeutic Effect
por: Hofer, Tamara, et al.
Publicado: (2021) -
Cell-penetrating peptides—the Swiss Army knife of cancer vaccines
por: Walker, Paul R., et al.
Publicado: (2015) -
Novel Protein-Based Vaccine against Self-Antigen Reduces the Formation of Sporadic Colon Adenomas in Mice
por: Belnoue, Elodie, et al.
Publicado: (2021) -
A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner
por: Auderset, Floriane, et al.
Publicado: (2020) -
ATP128 Clinical Therapeutic Cancer Vaccine Activates NF-κB and IRF3 Pathways through TLR4 and TLR2 in Human Monocytes and Dendritic Cells
por: Pascolutti, Roberta, et al.
Publicado: (2022)